GP120: Biologic aspects of structural features

被引:202
作者
Poignard, P
Saphire, EO
Parren, PWHI
Burton, DR
机构
[1] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
关键词
HIV-1; HIV envelope protein gp120; HIV antibodies; neutralization; AIDS vaccines;
D O I
10.1146/annurev.immunol.19.1.253
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV-1 particles are decorated with a network of densely arranged envelope spikes on their surface. Each spike is formed of a trimer of heterodimers of the gp120 surface and the gp41 transmembrane glycoproteins. These molecules mediate HIV-1 entry into target cells, initiating the HIV-1 replication cycle. They are a target for entry-blocking drugs and for neutralizing Abs that could contribute to vaccine protection. The crystal structure of the core of gp120 has been recently solved. It reveals the structure of the conserved HIV-1 receptor binding sites and some of the mechanisms evolved by HIV-1 to escape Ab responses. The gp120 consists of three faces. One is largely inaccessible on the native trimer, and two faces are exposed but apparently have low immunogenicity, particularly on primary viruses. We have modeled HIV-1 neutralization by a CD4 binding site monoclonal Ab, and we propose that neutralization takes place by inhibition of the interaction between gp120 and the target cell membrane receptors as a result of steric hindrance. Knowledge of gp120 structure and function should assist in the design of new drugs as well as of an effective vaccine. In the latter case, circumventing the low immunogenicity of the HIV-1 envelope spike is a major challenge.
引用
收藏
页码:253 / 274
页数:26
相关论文
共 110 条
[1]   CARBOHYDRATE DRAMATICALLY INFLUENCES IMMUNE REACTIVITY OF ANTISERA TO VIRAL GLYCOPROTEIN ANTIGENS [J].
ALEXANDER, S ;
ELDER, JH .
SCIENCE, 1984, 226 (4680) :1328-1330
[2]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[3]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[4]   Neutralizing antiviral B cell responses [J].
Bachmann, MF ;
Zinkernagel, RM .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :235-270
[5]   Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation [J].
Bandres, JC ;
Wang, QF ;
O'Leary, J ;
Baleaux, F ;
Amara, A ;
Hoxie, JA ;
Zolla-Pazner, S ;
Gorny, MK .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2500-2504
[6]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[7]  
Bieniasz Paul D., 1998, Frontiers in Bioscience, V3, pD44
[8]   Analysis of the interaction of antibodies with a conserved, enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120 [J].
Binley, JM ;
Wyatt, R ;
Desjardins, E ;
Kwong, PD ;
Hendrickson, W ;
Moore, JP ;
Sodroski, J .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (03) :191-198
[9]   A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure [J].
Binley, JM ;
Sanders, RW ;
Clas, B ;
Schuelke, N ;
Master, A ;
Guo, Y ;
Kajumo, F ;
Anselma, DJ ;
Maddon, PJ ;
Olson, WC ;
Moore, JP .
JOURNAL OF VIROLOGY, 2000, 74 (02) :627-643
[10]   HIV-1 entry - an expanding portal for drug discovery [J].
Blair, WS ;
Lin, PF ;
Meanwell, NA ;
Wallace, OB .
DRUG DISCOVERY TODAY, 2000, 5 (05) :183-194